Invivyd Welcomes Ajay Royan Back to the Board to Drive Innovation in Monoclonal Antibody Therapies

Invivyd, Inc. (Nasdaq: IVVD) has announced the return of Ajay Royan to its Board of Directors, bringing his expertise in transformative healthcare investments to the company’s mission. As the founder of investment firm Mithril and a key advocate for Invivyd’s strategic direction, Royan played a pivotal role in refocusing the company on delivering protection against serious viral infectious diseases. His leadership comes at a crucial time as Invivyd advances its monoclonal antibody platform, offering new hope for immunocompromised individuals facing the ongoing threat of COVID-19 and other infectious diseases.

With a deep commitment to innovation and rapid response, Royan emphasizes the urgent need to develop scalable, high-impact antibody therapies beyond traditional vaccines. He highlights the importance of addressing the unmet needs of vulnerable populations, including cancer patients, transplant recipients, and those with immunodeficiencies. Drawing inspiration from past public health initiatives, Royan envisions a collaborative effort with industry leaders and policymakers to accelerate the delivery of life-saving treatments. His return to the Board signals a renewed focus on leveraging proven American technology to protect those at the highest risk.